Sign up


Match Document Document Title
8968746 Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation  
The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably...
8968744 Aqueous composition comprising a biological antigen and an acrylic acid polymer  
The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity...
8961957 Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10  
The invention relates to therapy and methods of applying the therapy to cancer patients. The invention includes introducing intratumorally cytotoxic T lymphocyte and/or NKT cells, and prior to,...
8961983 Mucosal vaccine using cationic nanogel  
A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a...
8956627 Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates  
The present invention relates to a method of inducing the production in a patient of anti-HIV antibodies. The method comprises administering to a patient in need thereof an amount of at least one...
8951532 A25 bacteriophage lysin  
The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life...
8951529 Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases  
Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the...
8951538 Exopolysaccharide of Shigella sonnei bacteria, method for producing same, vaccine and phamaceutical composition containing same  
For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural...
8951531 Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides  
This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against...
8945591 Methods and compositions involving immunostimulatory oligodeoxynucleotides  
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, s...
8946175 Stabilized immunomodulatory oligonucleotides  
The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5′- or 3′-end. These oligonucleotides have either reduced or imp...
8945590 Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)  
This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for...
8945587 Synthetic lipid biology for combinatorial engineering of endotoxin  
The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different...
8945566 Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease  
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the...
8940310 Methods of treatment using TLR7 and/or TLR9 inhibitors  
The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory...
8936789 Immunoenhancer-linked oligomeric HIV envelope peptides  
Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an...
8936793 Synthetic archaeal glycolipid adjuvants  
Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as...
8933011 Treatment of preterm labor with toll-like receptor 9 antagonists  
The invention provides a method for treating or preventing preterm labor in pregnant female subjects. The method comprises the step of administering a therapeutically effective amount of a...
8932595 Nicotine immunonanotherapeutics  
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in...
8933029 Antimicrobial and anti-inflammatory peptides  
Antimicrobial and/or anti-inflammatory peptide compositions and therapeutic uses thereof are provided. The peptides and analogs or derivatives thereof may be used as an antimicrobial agent and/or...
8932594 Adjuvants and methods of use  
Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed....
8932846 Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins  
Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The...
8926961 HPV E6 protein T cell epitopes and uses thereof  
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its...
8926995 Adjuvant  
The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and...
8926983 Method for improving memory in AD patients  
The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize...
8921311 Method for treating hyperglycemia  
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting...
8920774 Drug having regulatory cell ligand contained in liposome  
A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.
8920809 Chimera comprising bacterial cytotoxin and methods of using the same  
This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the...
8916164 Methods of enhancing adjuvaticity of vaccine compositions  
The immunogenicity of vaccines is enhanced by co-administering a synthetic glycolipid, designated PBS-57, with the vaccine. PBS-57 has the ability to stimulate both a cell-mediated and humoral...
8916173 Acellular pertussis vaccine  
Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and...
8911749 Vaccine delivery via microneedle arrays  
A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have...
8911748 Cholera toxin chimera and its use as a staph vaccine  
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of...
8906381 Immunonanotherapeutics that provide IGG humoral response without T-cell antigen  
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune...
8906374 Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors  
The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR...
8906380 Fungal immunostimulatory compositions  
Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14+ mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction...
8900564 Vaccine composition comprising an antigen and a peptide having adjuvant properties  
The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a pos...
8900604 Fatty acid conjugates of quetiapine, process for making and using the same  
The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and...
8894996 Immunoadjuvant composition and use thereof  
Disclosed is a composition comprising, as an active ingredient, at least one selected from the group consisting of a Zc3h12a gene inhibitor and a Zc3h12a protein inhibitor. This composition can be...
8889121 Bacterium comprising a regulated rfaH nucleic acid  
The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present...
8889144 PCSK9 vaccine  
The present invention relates to the provision of immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated...
8889152 Capsular polysaccharides solubilisation and combination vaccines  
Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide,...
8889153 Combination of immunomodulator and anti-pathogenic agent  
A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the...
8883174 Compositions for stimulation of mammalian innate immune resistance to pathogens  
Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising...
8883724 Active antiangiogenic therapy  
Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in...
8877191 Antibodies to the PcrV antigen of Pseudomonas aeruginosa  
The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
8871732 Immunostimulatory sequence oligonucleotides and methods of using the same  
The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
8871436 Immunostimulatory oligonucleotides and uses thereof  
Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C, T, G or A (preferably T or C); X2 is C, T, G or A; X7 is C, T, G or A (preferably G); at least...
8858962 Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration  
An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not...
8858952 Methods and materials for generating T cells  
The document provides to methods and materials for generating T cells (e.g., antigen-specific CD4+ T cells). For example, methods and materials for using nested MHC class II epitopes as vaccines to...
8858958 Adjuvant comprising aluminum, oligonucleotide and polycation  
An immunological adjuvant comprises an aluminum salt, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other...